Healthpeak Properties Inc DOC

Thesis

Healthpeak Properties is a healthcare REIT with three segments: outpatient medical buildings (largely on hospital campuses, post the March 1, 2024 merger with Physicians Realty Trust), life-science lab properties (concentrated in South San Francisco, San Diego, and Boston/Cambridge), and a small CCRC (continuing care retirement community) book. The compounding case is structural demographics — the over-65 cohort grows roughly 3% annually through 2035 — combined with a real-asset moat: replacement cost on Class-A lab and on-campus medical office is materially above book, supply is constrained by zoning and entitlement, and tenants are sticky because moving a wet lab or a hospital-affiliated practice is operationally disruptive.

The scorecard is misleading on the surface. ROIC 10y average prints 0.0 and FCF conversion 0.0 — these reflect REIT GAAP, where depreciation on long-lived real estate crushes net income but does not reflect economic owner earnings. P/E TTM of 45.6x is also a REIT artifact. The metrics that matter — net debt/EBITDA at 8.87x (high but typical for the asset class), owner earnings TTM of $534.6M, and reverse-DCF implied growth of 4.6% — paint a more reasonable picture.

The IV math is unforgiving. IV base = $14.25, IV high = $21.17, current price = $16.42, P/IV = 1.15. The stock trades at a 15% premium to base case with only 29% upside to bull case. Margin of safety arrives below $12 (roughly IV-base less 15%). Buffett-style discipline says wait. Recommendation: Hold; trim above $19; accumulate below $12.

Moat

Healthpeak's moat sits in the cost-advantage and intangibles buckets, not pricing power or network effects. Buffett's framework rewards businesses where replacement cost protects incumbents and where switching costs lock in tenants for long periods. Both apply here, but in muted form.

Cost advantage / replacement cost barrier. Class-A lab buildings in South San Francisco, San Diego/Torrey Pines, and Cambridge/Boston cannot be replicated cheaply. Wet labs require specialized HVAC (100% outside air, high air changes per hour), backup power, vibration isolation, chemical waste handling, and 14-18 foot floor-to-floor heights. Replacement cost runs $1,000-1,400/sf. Entitled land in these submarkets is effectively rationed — zoning, neighborhood opposition, and seismic codes constrain new supply. Healthpeak's outpatient medical portfolio, post the DOC merger, is approximately 60% on hospital campuses, where the health system controls the ground and new competing buildings are economically and politically blocked. This echoes Buffett's BHE thesis [3]: regulators welcome incumbents who can deploy 'unlimited capital to fund whatever projects make sense' — Healthpeak's investment-grade balance sheet and relationships with health systems are the analog.

Switching costs (intangibles). A biotech that builds out a wet lab spends $200-400/sf in tenant improvements amortized over a 7-10 year lease. Mid-lease relocation means abandoning that capex, requalifying instruments, and disrupting cell-line work — operationally near-impossible for a Phase II/III program. Outpatient medical tenants who join a hospital's referral ecosystem face similar friction: moving off-campus risks losing the referral pipeline. Healthpeak's lab same-store NOI growth has historically tracked 3-5%; outpatient medical 2-3%. These are credible switching-cost signatures, not pricing power.

Stress test ($10B + 5 years). Could a competitor with $10B and 5 years dent Healthpeak? Partially. Blackstone's BioMed Realty already does in lab — and is arguably better. Welltower (WELL) is a stronger operator in senior housing/CCRC. In outpatient medical, Healthpeak is now (post-DOC merger) one of the two largest players alongside HTA/Healthcare Realty. So the competitive set is concentrated, but Healthpeak is not the dominant #1 in any segment — it is a strong #2 across three segments, which is a weaker structural position than a focused #1.

Erosion risk. The lab moat narrowed materially in 2023-2024. Biotech IPO drought, layoffs at large biopharma, and a 2020-2022 lab development boom have pushed lab vacancy in South San Francisco above 25% and in Cambridge above 20%. Mark-to-market on lab releasing has flipped negative in some submarkets. This is not a permanent impairment but it is a real cyclical hit that compresses near-term AFFO growth and explains why ROIC has been weak.

Pricing power: weak. Lease escalators are typically 2.5-3% fixed or CPI-capped. Healthpeak cannot raise rent on existing leases beyond contractual bumps; releasing spreads depend on submarket supply/demand. This is a real-asset business, not a See's Candy [5]-style pricing-power business.

Network effects: none. Tenants don't pick Healthpeak because other tenants are there.

Intangibles: modest. Brand and developer reputation matter for ground-up lab development (anchor biotech tenants prefer experienced developers), but Alexandria (ARE) is the gold-standard brand here, not Healthpeak.

Capital intensity caveat. REITs are capital-intensive by definition. Healthpeak's $20B+ asset base earns mid-single-digit cash yields on real estate. The 'moat' is largely the asset itself, not a return-on-capital signature like a See's or a Coca-Cola. Buffett owns very few REITs for this reason — the compounder math doesn't work the same way.

Moat verdict: NARROW.

Management & Capital Allocation

The 5-choice framework: reinvest, acquire, debt, buybacks, dividends — plus communication.

Acquire. The defining capital allocation event is the March 1, 2024 all-stock merger with Physicians Realty Trust (DOC, the ticker that survived). Headline rationale: scale in outpatient medical, $40-60M of synergies, complementary on-campus footprints. The structure was a stock-for-stock merger of equals at announcement, executed at a moment when both stocks were trading near multi-year lows (2023 REIT drawdown). This is mixed: issuing stock at a depressed multiple to buy depressed assets is value-neutral arithmetically but signals weakness — Buffett prefers cash deals or buybacks at low multiples, not stock deals at low multiples [6]. Transaction and merger-related costs were $122M in 9M 2024 and another $18M in 9M 2025, plus management distraction. The verdict on the deal will hinge on whether realized synergies exceed the integration cost and whether the larger outpatient platform actually delivers higher releasing spreads.

Reinvest. Healthpeak develops lab and outpatient medical on its own land. Yields-on-cost have historically been 6.5-7.5% in lab and 7-8% in outpatient medical, against cap rates on stabilized assets of 5-6%. Spread-to-cap-rate is the value creation. However, the 2023-2024 lab oversupply means new lab development now faces lease-up risk and concession packages, compressing realized yields. Healthpeak prudently slowed lab starts in 2024 — a credit to management discipline.

Debt. Net debt/EBITDA at 8.87x is high, even by REIT standards (peer avg ~6x). This is partly post-merger leverage that should de-lever via EBITDA growth, but it leaves no room for a second downturn. Interest coverage at 0.0 in the scorecard is a calculation artifact (the scorer divides by a depressed EBIT), but the real interest expense is $225M on $2.1B revenue — about 11% of revenue, manageable but not trivial. Weighted average interest rate has been creeping up as fixed-rate maturities refinance into a higher-rate environment.

Buybacks. Share count has grown 4.2% over 10 years (the merger was a major step-up in 2024). Healthpeak has not been a meaningful buyer of its own stock at a discount to IV — a missed Buffett-style opportunity in 2023 when DOC and PEAK both traded below NAV. Capital allocator score docked here.

Dividends. REITs must distribute 90% of taxable income; the dividend is roughly $1.20/year, ~7.3% yield at $16.42. AFFO payout ratio is approximately 80-85% — covered, but no margin to absorb a 20% AFFO decline without cutting the dividend. The 2020 COVID-era dividend cut (PEAK reduced from $1.48 to $1.20) is in living memory and demonstrates this is not a Coca-Cola-style sacrosanct dividend.

Communication. Healthpeak reports clearly in the 10-Q and earnings presentations, segments are well-defined (outpatient medical, lab, CCRC), and the AFFO bridge is disclosed. CEO Scott Brinker (former Welltower) brings credibility. No detected accounting shenanigans. Communication is above average for a REIT.

Synthesis. This is a solid B-grade capital allocator: disciplined developer, reasonable underwriter, honest reporter. The DOC merger was defensible but not heroic; the failure to buy back stock at deep discounts in 2023 is a real demerit; leverage is the highest in the peer set. Compared to Welltower's recent execution (WELL) or Alexandria's (ARE) lab-focused discipline, Healthpeak is middle of the pack — not bad, not exceptional.

Capital allocator: B.

Industry Structure

Threat of new entrants: MODERATE-LOW. Capital is plentiful but supply is constrained by zoning, entitlement, and replacement cost in the trophy lab submarkets and on-campus medical office. New REITs do not appear; existing REITs and private capital (Blackstone, KKR Real Estate) compete for assets. Barriers exist but they protect incumbents collectively, not Healthpeak specifically.

Bargaining power of buyers (tenants): MODERATE-HIGH and rising. Lab tenants have gained leverage in 2023-2025 as vacancy ballooned in South San Francisco (>25%) and Cambridge (>20%). Concession packages (free rent, higher TI allowances) have expanded. Outpatient medical tenants — primarily health systems and physician groups — are price-takers when on a hospital campus but have alternatives (off-campus medical office, ambulatory surgery centers) for specialty services. Tenant concentration is low (top-10 tenants <30% of revenue), which mutes single-tenant risk but doesn't enhance pricing power.

Bargaining power of suppliers: MODERATE. Construction labor and materials inflation hit 2021-2024 hard, raising development costs 15-25%. Land in trophy submarkets is the binding supplier and is effectively rationed. Healthpeak has long-tenured relationships with health systems for ground leases, which reduces supplier risk versus pure speculative developers.

Threat of substitutes: MODERATE. Telemedicine substitutes for some primary care visits, reducing space demand per physician — a slow-moving but real headwind for outpatient medical. Lab work is less substitutable; in-silico drug discovery (AI/ML) reduces some bench work but most therapeutic-modality validation still requires wet-lab space. CCRC faces substitution from home-based care and aging-in-place, which is the structural headwind in that segment industry-wide.

Rivalry: HIGH. Three large public peers (Healthpeak, Welltower, Ventas) plus Alexandria in lab, plus Healthcare Realty in outpatient medical, plus Blackstone-owned BioMed in lab, plus a long tail of private capital. M&A is an outlet (DOC merger, HR/HTA merger), but on the operating side rivalry is intense. Cap rate compression in 2020-2022 followed by cap rate expansion in 2023-2024 has whipsawed valuations.

Value pool location and trajectory. The value pool in healthcare real estate sits with: (1) the asset itself (real estate appreciation + rent escalators), (2) development spread (yield-on-cost above stabilized cap rates), and (3) operating efficiency (cost discipline, leasing acumen). It does NOT sit with the REIT structure capturing tenant economics — tenants keep their own profits. The trajectory of the value pool is mildly favorable on demographic tailwinds, mildly unfavorable on lab oversupply (2023-2026 work-through period) and on rate sensitivity. Cap rates appear to have peaked in late 2024 and are stabilizing as the Fed has paused; this is a tailwind for NAV.

Industry verdict: Average. Healthcare real estate has real demographic tailwinds and meaningful supply constraints in trophy submarkets, but it is capital-intensive, leveraged, rate-sensitive, and structurally unable to generate compounding-machine ROIC. Buffett famously avoids most REITs for these reasons.

Industry Verdict: Average.

Inversion (Bear Case)

Playing the short-seller. No hedging.

1. The single event that kills this. A sustained period of 5%+ 10-year Treasury yields combined with a credit-spread widening of 150bp on BBB REIT paper. Healthpeak refinances roughly $400-600M annually; at materially higher rates, weighted-average interest expense rises 100-150bp on $8B+ of debt over five years, costing $80-120M annually of AFFO — a 15-20% AFFO hit on top of any operating weakness. Combined with covenant pressure at 8.87x leverage, this forces an equity raise at a depressed price (highly dilutive to current holders) or a dividend cut. The 2020 dividend cut from $1.48 to $1.20 shows management will not defend the dividend at the cost of the balance sheet. A second cut to $0.80-0.90 would mark the stock to a $9-11 range mechanically.

2. Why the moat is narrower than bulls think. Bulls point to 'irreplaceable' lab buildings in South San Francisco and Cambridge. Reality: those submarkets just had a 25%+ vacancy event because supply was, in fact, replicable — thousands of square feet of speculative lab came online in 2022-2024. The 'replacement cost moat' protects against new supply only when capital is rational; in the 2020-2022 zero-rate era, capital was not rational, and the supply hangover will take 3-5 years to absorb. Outpatient medical 'on-campus' protection is real but Healthpeak does NOT own all the on-campus buildings — health systems are increasingly building their own MOBs and using REIT capital only opportunistically. The negotiating leverage has shifted toward health systems, not toward REITs. Healthpeak is not the dominant #1 in any segment; it is #2 or #3 in each of three segments — a structurally weaker position than a focused leader.

3. Why management is worse than it appears. The 2024 DOC merger was struck when both stocks traded at 60-70% of pre-2022 highs — i.e., management chose to issue depressed currency to buy depressed assets, when the value-creating move was to buy back its own stock at the same discount. The 'synergies' narrative was sell-side cover. Net debt/EBITDA at 8.87x is meaningfully above the peer median (~6x for Welltower, ~5.5x for Ventas) — Healthpeak operates with more leverage and less margin for error than peers. The previous CEO regime that created the company via the 2017 RIDEA spinoff and 2020 senior housing exit was a serial restructurer, not a compounder. The current CEO is competent but the platform he inherited has structural drag.

4. What bulls are extrapolating that won't hold. Bulls extrapolate (a) lab releasing spreads of 20-30% from 2018-2022 — those will not repeat; current releasing spreads are flat to negative; (b) 5-7% AFFO/share growth — actual 5-year AFFO/share CAGR has been roughly flat after netting share issuance; (c) cap rate compression as rates fall — cap rates may stabilize but will not return to 2021 lows because the marginal buyer's cost of capital has reset; (d) demographic tailwind translating into pricing power — demographics drive volume, not price, and Healthpeak's lease escalators are contractually capped at 2.5-3%.

5. Valuation trap (multiple compression / regime change). The IV math: IV base $14.25, current $16.42, P/IV 1.15. The bull case ($21.17) requires AFFO multiple expansion from current ~14x to ~18x — a re-rating that depends on rates falling AND lab oversupply clearing AND merger synergies materializing. Three-factor bull case. The bear case requires only one factor going wrong: rates stay high, OR lab vacancy persists, OR a dividend cut, OR an integration stumble. In a regime change scenario where 10-year yields settle at 4.5-5% as the new normal, healthcare REITs trade at 11-13x AFFO, not 14-16x. That multiple compression alone takes the stock to $11-12. Add a dividend cut and you're at $9.

If I am right, the stock could be worth $9 within 2-3 years.

Lollapalooza Bias Check

Biases active in the analyst right now:

Anchoring. I am anchored to the scorecard's IV base of $14.25 and IV high of $21.17. These were generated by deterministic Python from inputs that may have used industry-average multiples that don't fit a leveraged, rate-sensitive REIT. The $14.25 number is doing a lot of work in my recommendation; if the true IV-base were $11, my Hold flips to Avoid. I am leaning on the scorer because the prompt instructs me to, but I should flag that REIT IV calculations from generic frameworks systematically over-value because they don't haircut for leverage and rate sensitivity.

Authority / commitment. Buffett famously avoids most REITs and is on record skeptical of leveraged real estate as a compounder. I am partly relying on that authority to lean bearish. But Buffett also owned STORE Capital — so the categorical 'no REITs' rule is not absolute. I should evaluate Healthpeak on its own merits, not on a Buffett anti-REIT prior.

Recency. The 2023-2024 lab oversupply story is fresh and dominant. I may be over-weighting it. Lab vacancy peaked roughly 12-18 months ago in many submarkets; the 2026-2028 setup could be substantially better as biotech funding recovers. Recency bias pulls me toward extrapolating the 2024 narrative forward when the cycle may be turning.

Confirmation. I went into this analysis expecting a REIT to score poorly on the compounder framework (low ROIC, high leverage, capital-intensive). The scorer confirmed that prior with composite 52, ROIC 0%, FCF conversion 0%. I may have under-searched for the bull case — for example, the actual AFFO/share trajectory post-merger, or the lab releasing spread data for late-2025, which could be inflecting positive.

Deprival super-reaction (loss aversion at the stock level). The stock is down ~50% from 2022 highs. That drawdown creates both (a) a 'cheap' anchor that pulls toward Buy and (b) a 'broken' anchor that pulls toward Avoid. Both are emotional, not analytical. The price-to-IV ratio of 1.15 is the analytical answer: not cheap enough yet.

Incentive (mine, as analyst). There is mild incentive to issue a Buy — Buys are more useful to readers than Holds, and Holds feel intellectually lazy. I am resisting that pull. Hold is the correct answer at P/IV = 1.15 with narrow moat and high leverage.

Net effect. The biases mostly cancel. Anchoring and confirmation push bearish; recency pushes bearish; commitment to Buffett-style discipline pushes bearish; deprival/cheap-anchor and incentive push bullish. The IV math is the discipline: 15% above IV-base is not a Buffett buy.

10-Year Outlook

Same fundamental business model in 2035? Yes — owning healthcare real estate and collecting rent is unlikely to be disrupted as a business model. The asset mix may shift (more outpatient, less CCRC; more lab if biotech recovers, less if AI-driven drug discovery reshapes lab demand) but the core 'rent buildings to healthcare tenants' model is stable.

Customer base larger? Probably yes for outpatient medical (demographics). Uncertain for lab (depends on biotech funding cycle and drug-discovery technology). Lower for CCRC if aging-in-place trends accelerate.

Profit per customer higher? Marginally. Lease escalators of 2.5-3% compound; some mark-to-market upside if vacancy normalizes; offset by higher operating costs (insurance, property tax, energy) and higher refinancing rates. Real (inflation-adjusted) profit per customer is probably flat to up 1% annually.

Moat wider? No. The lab moat narrowed in 2023-2024 due to oversupply and may not fully recover. The outpatient medical moat is stable. The CCRC moat is stable but in a shrinking pond.

Single biggest threat (10-year horizon). Persistent higher-for-longer interest rates compressing REIT valuations and forcing dilutive equity raises. Secondary: technology shift (telemedicine + AI drug discovery) reducing aggregate healthcare real estate demand below replacement supply.

Confidence assessment. I can underwrite the directionality (rents will exist, demographics tailwind, supply constraints in trophy submarkets) but I cannot underwrite the magnitude with high confidence. Cap rates are macro-driven; refinancing risk is rate-driven; lab cycle is biotech-funding-driven — all three are outside Healthpeak's control. The 8.87x leverage amplifies all three. A focused leader (Welltower, Alexandria) would warrant medium confidence; Healthpeak as a #2-#3 in each of three segments warrants medium confidence at best.

CONFIDENCE: medium